Correlation between biomarkers and clinical outcomes
| Biomarker . | P value . | Hazard ratio . | HR lower CL . | HR upper CL . |
|---|---|---|---|---|
| Nonrelapse mortality by 2 y* | ||||
| ST2 | .00038 | 2.43 | 1.49 | 3.95 |
| IL-6† | .0090 | 3.80 | 1.39 | 10.33 |
| Reg3α | .00073 | 2.35 | 1.43 | 3.87 |
| TIM3 | <.0001 | 4.87 | 2.53 | 9.34 |
| Overall survival‡ | ||||
| ST2 | .0014 | 1.73 | 1.24 | 2.41 |
| IL-6† | .0022 | 2.42 | 1.37 | 4.25 |
| Reg3α | <.0001 | 2.00 | 1.46 | 2.73 |
| TIM3 | .00035 | 1.87 | 1.33 | 2.65 |
| Chronic GVHD§ | ||||
| ST2 | .30 | 1.13 | 0.89 | 1.44 |
| CXCL9† | .0069 | 1.60 | 1.14 | 2.26 |
| OPN | .06 | 0.73 | 0.52 | 1.01 |
| MMP3 | .90 | 0.99 | 0.85 | 1.16 |
| Biomarker . | P value . | Hazard ratio . | HR lower CL . | HR upper CL . |
|---|---|---|---|---|
| Nonrelapse mortality by 2 y* | ||||
| ST2 | .00038 | 2.43 | 1.49 | 3.95 |
| IL-6† | .0090 | 3.80 | 1.39 | 10.33 |
| Reg3α | .00073 | 2.35 | 1.43 | 3.87 |
| TIM3 | <.0001 | 4.87 | 2.53 | 9.34 |
| Overall survival‡ | ||||
| ST2 | .0014 | 1.73 | 1.24 | 2.41 |
| IL-6† | .0022 | 2.42 | 1.37 | 4.25 |
| Reg3α | <.0001 | 2.00 | 1.46 | 2.73 |
| TIM3 | .00035 | 1.87 | 1.33 | 2.65 |
| Chronic GVHD§ | ||||
| ST2 | .30 | 1.13 | 0.89 | 1.44 |
| CXCL9† | .0069 | 1.60 | 1.14 | 2.26 |
| OPN | .06 | 0.73 | 0.52 | 1.01 |
| MMP3 | .90 | 0.99 | 0.85 | 1.16 |
Proportional hazards model with time-dependent covariates adjusting for treatment group, age, and CMV status.
High vs low (see Patients and methods).
Proportional hazards model with time-dependent covariates adjusting for treatment regimen.
Proportional hazards model with time-dependent covariates adjusting for treatment group and primary malignancy.